AGO-OVAR 2.21

Trial Description: 
A prospective randomized Phase III trial of carboplatin/gemcitabine/bevacizumab vs. carbolatin/pegylated liposomal doxorubin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
Lead Cooperative Group: 
Participating Groups: 
Disease Site: 
Recurrent Ovarian
Trial Status: 
Follow Up
Contact person: